Cancer treatments, including chemotherapy, in addition to killing a large number of tumour cells, also result in the generation of senescent tumour cells (also called “zombie cells”). While senescent cells do not reproduce, they do, unfortunately, generate a favourable environment for the expansion of tumour cells that may have escaped the effects of the chemotherapy and eventually result in tumour regrowth.

An international team of researchers led by Dr Manuel Serrano at IRB Barcelona have described how cancer cells that have become senescent after chemotherapy activate the PD-L2 protein to protect themselves from the immune system while recruiting immune suppressor cells. The latter creates an inhibitory environment that impairs the ability of lymphocytes to kill cancer cells. Based on these findings, scientists wondered what would be the effect of inactivating PD-L2. Interestingly, senescent cells lacking PD-L2 are rapidly eliminated by the immune system. This intercepts the capacity of senescent cells to create an immunosuppressive environment and, as a result, lymphocytes retain their full capacity to kill those cancer cells that may have escaped the effects of chemotherapy.

“By blocking PD-L2 in mouse models, we have seen that chemotherapy is more effective against cancer. This finding paves the way to consider the use of a potential PD-L2 inhibitor as an adjuvant in the treatment of this disease,” explains Dr. Manuel Serrano, currently at Altos Labs (Cambridge, United Kingdom).

The study has been done using cell lines and animal models of melanoma, pancreatic and breast cancer.

Senescence — a common phenomenon in cancer therapies

Cellular senescence is a process that occurs naturally during ageing and it is common in the context of cancer therapies. Most of these treatments (such as chemotherapy and radiotherapy) act by causing extensive cellular damage and, as a result, bring about senescent cells, particularly within the tumour. The team of scientists will now study whether senescent cells linked to the ageing of the organism also exhibit elevated levels of PD-L2.

 “Although more experiments are needed to characterise the role of this molecule in different types of human cancers, this work has enhanced our understanding of the role of PD-L2 and the interaction of senescent cells with the immune system,” explains Dr José Alberto López, a postdoctoral researcher from the same laboratory and first author of the work together with Dr Selim Chaib. In 2024, Dr López will be starting a new laboratory at the Salamanca Cancer Research Center, a joint endeavour between the University of Salamanca and CSIC. Dr Chaib is now at the Mayo Clinic, in Minnesota (United States).

This work has been carried out in collaboration with the groups led by Drs Joaquín Arribas, Alena Gros and María Abad at the Vall d'Hebron Institute of Oncology (VHIO). Dr Arribas is now the director of the Hospital del Mar Research Institute (IMIM) and Dr. Abad works at Altos Labs. The team led by Drs. James Kirkland and Tamara Tchkonia at the Mayo Clinic contributed important data to this study. This work has also involved the company Rejuveron Senescence Therapeutics, which is developing antibodies against PD-L2 for clinical use and has central offices in Zurich and Barcelona.

This work has received funding from the Spanish Association Against Cancer, "la Caixa" Foundation, BBVA Foundation, the Spanish Ministry of Science and Innovation, the Ministry of Research and Universities of the Generalitat de Catalunya, the European Research Council (ERC) and ERDF European funds.

Source: Institute for Research in Biomedicine (IRB Barcelona)